Skip to main content
News

Investigational Sapablursen Shows Promise for Erythrocytosis Control in Polycythemia Vera

Edited by 

Key Clinical Summary

  • The phase 2a IMPRSSION trial found that sapablursen significantly reduced phlebotomy requirements among 49 patients with phlebotomy-dependent polycythemia vera (PV).
  • Estimated annual phlebotomy rates declined from 7.8 to 2.6 in cohort A and from 8.8 to 3.6 in cohort B.
  • Sapablursen improved hematocrit control and patient-reported symptoms, although anemia and fatigue were common adverse events.

An investigational treatment, sapablursen, significantly reduced phlebotomy requirements and improved hematocrit control among patients with polycythemia vera (PV), according to findings from the phase 2a IMPRSSION trial published in Blood. The results suggest that targeting iron regulation through hepcidin production may offer an alternative approach to managing erythrocytosis and reducing treatment burden in patients with PV.

Sapablursen Significantly Reduces Phlebotomy Requirements

The ongoing, randomized, open-label study enrolled 50 patients across 18 international sites, with 49 receiving treatment. Participants received subcutaneous sapablursen every 4 weeks in cohort A (120 or 80 mg; n = 32) or cohort B (40 mg; n = 17).

The primary endpoint evaluated changes in weekly phlebotomy frequency between baseline and weeks 17 through 37.

Both cohorts experienced statistically significant reductions in weekly phlebotomy rates, decreasing by 0.10 procedures per week (P < .0001 in cohort A; P = .0001 in cohort B).

Among patients completing the efficacy evaluation period, the median number of phlebotomies declined from 5 during the 26-week baseline period to 0 in cohort A and 1.5 in cohort B during the 20-week evaluation period.

Treatment success, defined as a greater than 90% reduction in phlebotomy frequency, occurred in 53% of cohort A and 41% of cohort B.

At week 37, mean hematocrit decreased from 46.4% to 40.5% in cohort A and from 45.5% to 43.5% in cohort B.

Clinical Implications for Polycythemia Vera Management

Maintaining hematocrit below 45% is a central treatment objective in PV because elevated levels are associated with increased thrombotic risk.

Sapablursen suppresses transmembrane serine protease 6 (TMPRSS6), increasing hepcidin production and restricting iron availability for red blood cell production.

Patient-reported symptom scores improved significantly in cohort A, with a mean reduction of 6.21 points on the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (P = .0052). The reduction in cohort B was not statistically significant.

Adverse events occurred in 92% of patients, most commonly anemia (37%) and fatigue (33%). Serious adverse events occurred in 18%, and 8% discontinued treatment because of adverse events.

For managed care stakeholders, reduced phlebotomy requirements represent a potentially relevant treatment outcome. However, the study did not evaluate health care utilization costs or cost-effectiveness, and its small sample size and lack of a placebo group limit conclusions about comparative effectiveness.

Investigators Highlight Potential for Further Development

The researchers concluded that sapablursen offers a "novel approach" to PV treatment focused on hematocrit control.

The authors acknowledged that the trial's limited size, follow-up duration, and open-label design prevented assessment of treatment effects on thrombotic events or disease progression.

The findings support further evaluation of sapablursen as a potential treatment for phlebotomy-dependent PV. A planned placebo-controlled phase 3 trial will investigate hematocrit control, phlebotomy reduction, safety, and patient-reported symptoms.

Reference

Palmer JM, How J, Bose P, et al. Sapablursen for erythrocytosis control in patients with polycythemia vera. Blood. 2026;148(20):2477-2488. https://doi.org/10.1182/blood.2026033792